GLG News Analyses of the following article:
Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Doceta
Published at: www.jco.org
-
Alimta vs Taxotere in Seniors: Lilly Wins?
September 19, 2006
Second line chemotherapy is worthwhile and tolerated well in seniors citizens, but Alimta (Eli Lilly) appears to be at least as effective as Taxotere (Sanofi-Aventis) with much less toxicity and with less premature patient withdrawals. There was a marked difference in the incidence of febrile neutropenia and the toxicity profile was better for the Lilly product.
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 9 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.